Venetoclax, an inhibitor of BCL-2, has recently been demonstrated in a Phase Ib dose-escalation study in ≥65 years of age with naive AML and ineligible for conventional treatment had favorable outcomes [189]. Here, BCL2 is linked to acute myeloid leukemia.